Combined integrated protocol/basket trial design for a first-in-human trial.
about
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera from Subjects Dosed with the Anti-C1s Monoclonal Antibody TNT009 - Results from a Randomized First-in-Human Phase 1 Trial.From promising molecules to orphan drugs: Early clinical drug developmentEffect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study.Analysis of integrated clinical trial protocols in early phases of medicinal product development.Drugs for rare disorders.Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial.
P2860
Combined integrated protocol/basket trial design for a first-in-human trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined integrated protocol/basket trial design for a first-in-human trial.
@en
Combined integrated protocol/basket trial design for a first-in-human trial.
@nl
type
label
Combined integrated protocol/basket trial design for a first-in-human trial.
@en
Combined integrated protocol/basket trial design for a first-in-human trial.
@nl
prefLabel
Combined integrated protocol/basket trial design for a first-in-human trial.
@en
Combined integrated protocol/basket trial design for a first-in-human trial.
@nl
P2093
P2860
P1476
Combined integrated protocol/basket trial design for a first-in-human trial.
@en
P2093
Bernd Jilma
Georg Böhmig
Georg Stingl
Jim Gilbert
Ulla Derhaschnig
Ulrich Jäger
P2860
P2888
P356
10.1186/S13023-016-0494-Z
P577
2016-10-04T00:00:00Z
P6179
1034258723